Glenmark Pharmaceuticals Limited (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC). Glenmark's Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC) has been determined by the FDA to be bioequivalent to the reference listed drug, Flonase Allergy Relief Nasal Spray, 50 mcg per spray, of Haleon US Holding LLC [NDA - 205434]; and will be distributed in the U.S. by Glenmark Therapeutics Inc., USA.

According to Nielsen syndicated data for the latest 52-week period ending March 3, 2026, the Flonase Allergy Relief Nasal Spray, 50 mcg per spray market achieved annual sales of approximately $384.7 million.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "We are excited to announce the recent approval of Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC). As the first approved nasal spray distributed by Glenmark Therapeutics Inc., USA in the OTC space, we look forward to bringing this quality over-thecounter solution to our customers when we launch in April 2026."